Andrew Leavitt, MD


Dr. Andrew Leavitt is director of the UCSF Non-Malignant Hematology Program and co-director of UCSF Comprehensive Hemophilia Treatment Center. He is a hematologist who treats patients with non-malignant blood diseases, including bleeding disorders such as hemophilia and von Willebrand disease, platelet function disorders, thrombocytopenia, including ITP, venous thromboembolic disorders, neutropenia and anemia. He also is the medical director of the Adult Blood and Marrow Transplant Laboratory and is internationally known for his studies of megakaryocyte development. His research also focuses on improving the treatment and outcome of patients with venous thromboembolic diseases.

Leavitt obtained a medical degree at Harvard Medical School. He completed an internal medicine residency and was chief medical resident at the University of Michigan, Ann Arbor, and completed a hematology and oncology fellowship and a transfusion medicine fellowship at UCSF. He joined the UCSF faculty in 1992 and is a professor-in-residence in the departments of Medicine and Laboratory Medicine. Leavitt has served on the editorial boards of the journal BLOOD and the Journal of Clinical Investigation. He currently serves on the editorial board of the Journal of Clinical and Translational Science.


Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Hemophilia Treatment Center
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Phone: (415) 353-2421
Fax: (415) 353-2467

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title


More about Andrew Leavitt


Harvard School of Medicine 1984


University of Michigan Hospital, Internal Medicine 1988


UCSF Medical Center, Hematology/Oncology 1991
UCSF Medical Center, Transfusion Medicine 1992

Selected Research and Publications

  1. Leavitt AD. A Small Step Closer But Not Yet There: Oral Anti-Xa Agents and the Treatment of Cancer-Associated Venous Thromboembolism. J Natl Compr Canc Netw. 2018 May; 16(5):572-574.
  2. Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Adv. 2017 Jul 11; 1(16):1224-1237.
  3. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017 04 06; 544(7648):105-109.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.